A dramatically distinct risk score existed between nonresponders and responders, suggesting that we could more accurately predict the GC patients’ clinical response to anti-PD-1/CTLA-4 immunotherapy through the MRHPPG risk score. This evidence concerns the gene CTLA4 and gastric cancer.